Skip to content
Study details
Enrolling now

A Study of LY4088044 in Healthy Participants

Eli Lilly and Company
NCT IDNCT07090785ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

104

Study length

about 2 years

Ages

18–65

Locations

4 sites in CA, KS, TX +1

About this study

This trial is testing a new drug called LY4088044 to see how well it's tolerated and what side effects might occur. The drug will be given either under the skin or into a vein, and blood tests will monitor its levels and elimination from the body. It lasts up to 92 weeks.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take LY4088044
  • 2.Take Placebo
PhasePhase 1
Primary goalNumber of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Secondary: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4088044, Pharmacodynamics (PD): Protein Levels in Skin Samples, Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4088044